AbstractImmune-mediated @entity1596 is a collective term referring to a group of potentially blinding intraocular @entity32 which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in @entity1596 , and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the @entity32 rapidly. They are administered locally when disease is confined to the @entity735 often requires systemic corticosteroid therapy,carrying a high risk of serious adverse effects when used for extended periods. In this situation, @entity134 -sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual @entity1 characteristics, cost, drug availability and physician preference. @entity1 should actively participate in therapeutic decision-making. Our first choice for @entity134 -sparing medication is often @entity1499 , an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe @entity1596 , we may combine the immunomodulating agent @entity205 with @entity1499 and a @entity228 . @entity500 and @entity786 are other treatment options. @entity134 -sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.

Management of immune-mediated XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'inflammations'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['Azathioprine'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid', 'steroid'] @entity735 :: ('MESH:D005124', 'Disease') :: ['anterior portion of the eye.However, posterior eye involvement'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity1596 :: (MESH:D014605,Disease) :: ['uveitis']
